| 7.61 -0.39 (-4.88%) | 11-07 10:01 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 10.11  |
1-year : | 11.68 |
| Resists | First : | 8.66 |
Second : | 10 |
| Pivot price | 8.14 |
|||
| Supports | First : | 6.5 |
Second : | 5.4 |
| MAs | MA(5) : | 7.75 |
MA(20) : | 8.28 |
| MA(100) : | 7.22 |
MA(250) : | 4.58 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 40.4 |
D(3) : | 33.9 |
| RSI | RSI(14): 49.4 |
|||
| 52-week | High : | 11.97 | Low : | 1.84 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ TAOX ] has closed above bottom band by 28.3%. Bollinger Bands are 45.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 8.18 - 8.22 | 8.22 - 8.26 |
| Low: | 7.39 - 7.44 | 7.44 - 7.48 |
| Close: | 7.91 - 7.99 | 7.99 - 8.06 |
Clinical-stage biopharmaceutical company developing a bryostatin‑1 platform for Alzheimer’s and other neurodegenerative/cognitive diseases. Also pivoting to a digital-asset treasury strategy focused on acquiring and staking TAO cryptocurrency.
Thu, 06 Nov 2025
TAO Synergies Bets Big On Decentralized AI Token Gains - Finimize
Tue, 04 Nov 2025
TAO Synergies (Nasdaq: TAOX) invests $750K, allocating $375K each into Yuma Subnet Funds - Stock Titan
Tue, 04 Nov 2025
TAO Synergies Announces Initial $750,000 Investment in Yuma Asset Management's Subnet Funds - Yahoo Finance
Mon, 03 Nov 2025
TAO Synergies makes its first $750,000 investment in Yuma Asset Management's Bittensor subnet fund - Bitget
Mon, 20 Oct 2025
TAO Synergies (TAOX) Expands Holdings and Secures Funding for Fu - GuruFocus
Mon, 20 Oct 2025
TAO Synergies stock soars after increasing Bittensor token holdings - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 3.33e+006 (%) |
| Held by Institutions | 1.8 (%) |
| Shares Short | 576 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.94e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -58 % |
| Return on Assets (ttm) | 959.8 % |
| Return on Equity (ttm) | -18.1 % |
| Qtrly Rev. Growth | 3960 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -75.8 |
| EBITDA (p.s.) | 1941.17 |
| Qtrly Earnings Growth | -21.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.11 |
| Price to Cash Flow | 2.27 |
| Dividend | 0 |
| Forward Dividend | 846600 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|